首页> 外文期刊>International Orthopaedics >Use of purified beta-tricalcium phosphate for filling defects after curettage of benign bone tumours.
【24h】

Use of purified beta-tricalcium phosphate for filling defects after curettage of benign bone tumours.

机译:刮除良性骨肿瘤后使用纯化的β-磷酸三钙填充缺损。

获取原文
获取原文并翻译 | 示例
           

摘要

Fifty-three patients with benign bone tumours were treated with curettage and filling with a purified beta-tricalcium phosphate (beta-TCP). Recurrences occurred in two cases. There was neither a postoperative infection nor adverse reaction due to the material. Postoperative fractures did not occur in any patients. Radiographically, complete resorption of the material and bone remodelling were achieved in 23 cases (43%). Of these 23 cases, there was a statistical correlation between the filling volume and the time taken for complete resorption (p<0.05). We concluded that purified beta-TCP was an ideal bone graft substitute for the treatment of benign bone tumours because of its good biocompatibility and resorption characteristics.
机译:对53例良性骨肿瘤患者进行刮除术,并用纯化的β-磷酸三钙(β-TCP)填充。有两例复发。由于材料原因,既没有术后感染也没有不良反应。所有患者均未发生术后骨折。放射学上,23例(43%)实现了材料的完全吸收和骨重塑。在这23例病例中,充盈量和完全吸收所需的时间之间存在统计学相关性(p <0.05)。我们得出的结论是,纯化的β-TCP由于其良好的生物相容性和吸收特性,是治疗良性骨肿瘤的理想骨移植替代品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号